FAM72, Glioblastoma Multiforme (GBM) and Beyond.
Nguyen Thi Thanh HoChinmay Satish RahaneSubrata PramanikPok-Son KimArne KutznerKlaus HeesePublished in: Cancers (2021)
Neural stem cells (NSCs) offer great potential for regenerative medicine due to their excellent ability to differentiate into various specialized cell types of the brain. In the central nervous system (CNS), NSC renewal and differentiation are under strict control by the regulation of the pivotal SLIT-ROBO Rho GTPase activating protein 2 (SRGAP2)-Family with sequence similarity 72 (FAM72) master gene (i.e., |-SRGAP2-FAM72-|) via a divergent gene transcription activation mechanism. If the gene transcription control unit (i.e., the intergenic region of the two sub-gene units, SRGAP2 and FAM72) gets out of control, NSCs may transform into cancer stem cells and generate brain tumor cells responsible for brain cancer such as glioblastoma multiforme (GBM). Here, we discuss the surveillance of this |-SRGAP2-FAM72-| master gene and its role in GBM, and also in light of FAM72 for diagnosing various types of cancers outside of the CNS.
Keyphrases
- copy number
- genome wide
- genome wide identification
- resting state
- white matter
- neural stem cells
- transcription factor
- signaling pathway
- cancer stem cells
- public health
- palliative care
- blood brain barrier
- papillary thyroid
- gene expression
- functional connectivity
- small molecule
- multiple sclerosis
- mesenchymal stem cells
- cell therapy
- young adults
- binding protein
- lymph node metastasis